Effect of panretinal photocoagulation on retinal nerve fiber layer thickness and vision-related quality of life in proliferative diabetic retinopathy patients
Keywords:
Proliferative diabetic retinopathy, panretinal photocoagulation, vision-related Quality of life, retinal nerve fiber layerAbstract
The purpose of this study is to evaluate the retinal nerve fiber layer (RNFL) thickness and vision-related quality of life (VRQoL) in type 2 diabetes mellitus (T2DM) patients with proliferative diabetic retinopathy (PDR) following panretinal photocoagulation (PRP). A prospective cohort study was conducted from June 2012 until December 2013. Visual acuity was evaluated using Snellen chart (converted to LogMAR decimal notation), RNFL thickness using optical coherence tomography and VRQoL using Visual Function Questionnaire-25 (VFQ-25) before and at three months after completed PRP. A total of 44 PDR patients were enrolled into this study. There was significant reduction of mean visual acuity at three months post PRP (p < 0.001). Both mean global RNFL thickness and mean composite score of VFQ-25 showed significant reduction at three months post PRP (p < 0.001 and p < 0.001 respectively). There was significant fair negative correlation between VFQ-25 composite score and LogMAR visual acuity post PRP (r = -0.425, p = 0.004). PRP was associated with reduction of RNFL thickness and VFQ-25 composite score in T2DM patient with PDR at three months post PRP. Longer duration of follow-up is recommended to look for the long-term effect of VRQoL from laser therapy.Â
References
Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologica. 2007;221:pp.95-102.
Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care. 2015;42:pp.451-64.
Cheung GC, Yoon YH, Chen LJ, Chen SJ, George TM, et al. Diabetic macular edema: Evidence-based treatment recommendations for Asian countries. Clin Exp Ophthalmol. 2018;46:pp75-86.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology. 2002;109:pp.920-927.
Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:pp.2044-2049.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular oedema. ETDRS report number 1. Arch Ophthalmology. 1985;103:pp.1796-1806.
The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings. DRS report number 8. Ophthalmology. 1981;88:pp.583-600.
Kaiser RS, Maguire MG, Grunwald JE, Lieb D, Jani B, et al. One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol. 2000;129:pp.178-185.
Woodcock A, Bradley C, Plowright R, Ffytche T, Kennedy-Martin T, et al. The influence of diabetic retinopathy on quality of life: Interviews to guide the design of a condition-specific, individualised questionnaire: the RetDQoL. Patient Educ Couns. 2004;53:pp.365-383.
Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, et al. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy. Diabet Med. 2006;23:pp.60-66.
Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:pp.1050-1058.
Soman S, Ganekal S, Nair U, Nair K. Effect of panretinal photocoagulationon macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema. Clin Ophthalmol. 2012;6:pp.2013–2017.
Mukhtar A, Khan MS, Junejo M, Ishaq M, Akbar B. Effect of pan retinal hotocoagulation on central macular thickness and visual acuity in proliferative diabetic retinopathy. Pak J Med Sci. 2016;32:pp.221-224.
McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1985;92:pp.388-393.
Lorusso M, Milano V, Nikolopoulou E, Ferrari LM, Cicinelli MV, et al. Panretinal photocoagulation does not change macular perfusion in eyes with proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2019;50:pp.174-178.
Dogru M, Nakamura M, Inoue M, Yamamoto M. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43:pp.217-224.
Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007;27:pp.816-824.
Wan-Wei L, Sakinah Z, Zunaina E. Effects of contact and non-contact laser photocoagulation therapy on ocular surface in patients with proliferative diabetic retinopathy. J of Biomed & Clin Sci. 2019;4:pp.1-6.
Muqit MMK, Wakely L, Stanga PE, Henson DB, Ghanchi FD. Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy. Eye. 2010;24:pp.1136-1142.
Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research Group. Retinal neurodegeneration: Early pathology in diabetes. Clin Exp Ophthalmol. 2000;28:pp.3-8.
Chihara E, Matsuoka T, Ogura Y, Matsumura M. Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology. 1993;100:pp.1147-1151.
Kim HY, Cho HK. Peripapillary retinal nerve fiber layer thickness change after panretinal photocoagulation in patients with diabetic retinopathy. Korean J Ophthalmol. 2009;23:pp.23-26.
Yazdani S, Samadi P, Pakravan M, Esfandiari H, et al. Peripapillary RNFL thickness changes after panretinal photocoagulation. Optom Vis Sci. 2016;93:pp.1158-1162.
Lim MC, Tanimoto SA, Furlani BA, Lum B, Pinto LM, et al. Effect of diabetic retinopathy and panretinal photocoagulation on retinal nerve fiber layer and optic nerve appearance. Arch Ophthalmol. 2009;127:pp.857-862.
Sharma S, Oliver-Fernandez A, Liu W, Buchholz P, Walt J. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol. 2005;16:pp.155-159.
Russell PW, Sekuler R, Fetkenhour C. Visual function after pan-retinal photocoagulation: a survey. Diabetes Care. 1985;8:pp.57-63.
Diab B, Khachman D, Farah R, Echtay A, Zein S. Type 2 Diabetes and comorbidity among Internal Medicine Lebanese Patients: A case control study. JDMC. 2019;1:pp.4-7.
Misliza A, Mas Ayu S. Sociodemographic and lifestyle factors as the risk of diabetic foot ulcer in the University of Malaya Medical Centre. JUMMEC. 2009;12:pp.15-21.
Peng PH, Laditka SB, Lin HS, Lin HC, Probst JC. Factors associated with retinal screening among patients with diabetes in Taiwan. Taiwan J Ophthalmol. 2019;9:pp.185-93.
Downloads
Additional Files
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
